Original Article

You have full text access to this OnlineOpen article

A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment †

Impact on survival and bleeding complications

  1. Nicole M. Kuderer MD*,
  2. Alok A. Khorana MD,
  3. Gary H. Lyman MD, MPH,
  4. Charles W. Francis MD

Article first published online: 17 JUL 2007

DOI: 10.1002/cncr.22892

Issue

Cancer

Cancer

Volume 110, Issue 5, pages 1149–1161, 1 September 2007

Additional Information

How to Cite

Kuderer, N. M., Khorana, A. A., Lyman, G. H. and Francis, C. W. (2007), A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment . Cancer, 110: 1149–1161. doi: 10.1002/cncr.22892

Author Information

  1. James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York

*Department of Medicine, Duke University Medical Center, Duke Comprehensive Cancer Center, 3829 Duke South, Mailbox DUMC3841, Durham, NC 27710

  1. †

    Presented in part at the American Society of Clinical Oncology Venous Thrombosis Guideline Committee Meeting, July 2006.

Publication History

  1. Issue published online: 20 AUG 2007
  2. Article first published online: 17 JUL 2007
  3. Manuscript Accepted: 5 MAY 2007
  4. Manuscript Revised: 21 MAR 2007
  5. Manuscript Received: 25 JAN 2007

Funded by

  • American Society of Clinical Oncology
  • National Institutes of Health. Grant Number: T32HL07152-30
  • National Cancer Institute. Grant Number: 1K23 CA120587-01A1

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (329K)

REFERENCES

  • 1
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000; 160: 809–815.
  • 2
    White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med. 2005; 165: 1782–1787.
  • 3
    Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am. 1996; 10: 499–530.
  • 4
    Rickles FR, Levine MN. Epidemiology of thrombosis in cancer. Acta Haematol. 2001; 106(1–2): 6–12.
  • 5
    Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis. 1998; 28( suppl 3): 50–60.
  • 6
    Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004; 2: 2156–2161.
    Direct Link:
  • 7
    Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung. Cancer. 1990; 65: 481–485.
    Direct Link:
  • 8
    Rickles FR. Abnormalities of blood coagulation in patients with cancer. In: Neri SerneriGG, GensiniGF, AbbateR, PriscoD, editors. Thrombosis. An Update. Florence, Italy: Scientific Presse; 1992: 241–260.
  • 9
    Iberti TJ, Miller M, Abalos A, et al. Abnormal coagulation profile in brain tumor patients during surgery. Neurosurgery. 1994; 34: 389–394; discussion, 394–385.
  • 10
    von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost. 1997; 77: 456–461.
  • 11
    Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992; 327: 1128–1133.
  • 12
    Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998; 338: 1169–1173.
  • 13
    Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venousthromboembolism and cancer. Lancet. 1998; 351: 1077–1080.
  • 14
    Nierodzik M, Karpatkin S. Hypercoagulability preceding cancer. Does hypercoagulability awaken dormant tumor cells in the host? J Thromb Haemost. 2005; 3: 577–580.
    Direct Link:
  • 15
    Falanga A. The effect of anticoagulant drugs on cancer. J Thromb Haemost. 2004; 2: 1263–1265.
    Direct Link:
  • 16
    Rosenbaum J, Tobelem G, Molho P, Barzu T, Caen JP. Modulation of endothelial cells growth induced by heparin. Cell Biol Int Rep. 1986; 10: 437–446.
  • 17
    Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst. 1999; 91: 22–36.
  • 18
    Regelson W. Anionic dyes, heparin, and heparinoids: the rediscovery of polyanionic tumor inhibitors. J Natl Cancer Inst. 1989; 81: 1929–1930.
  • 19
    Agostino D, Cliffton EE. Anticoagulants and the development of pulmonary metastases. Anticoagulant effect on the Walker 256 carcinosarcoma in rats. Arch Surg. 1962; 84: 449–453.
  • 20
    Agostino D, Grossi CE, Cliffton EE. Effect of heparin on circulating Walker carcinosarcoma 256 cells. J Natl Cancer Inst. 1961; 27: 17–24.
  • 21
    Hagmar B. Effect of heparin, epsilon-aminocaproic acid and coumarin on tumour growth and spontaneous metastasis formation. Pathol Eur. 1968; 3: 622–630.
  • 22
    Hagmar B, Norrby K. Evidence for effects of heparin on cell surfaces influencing experimental metastases. Int J Cancer. 1970; 5: 72–84.
    Direct Link:
  • 23
    Hilgard P, Beyerle L, Hohage R, Hiemeyer V, Kubler M. The effect of heparin on the initial phase of metastasis formation. Eur J Cancer. 1972; 8: 347–352.
  • 24
    Kiricuta I, Todorutiu C, Muresian T, Risca R. Prophylaxis of metastases formation by unspecific immunologic stimulation associated with heparintherapy. Cancer. 1973; 31: 1392–1396.
    Direct Link:
  • 25
    Ivarsson L, Rudenstam CM. Heparin, dextran 1000 and metastasis formation after I.V. tumour cell injection in dextran non-sensitive rats. Br J Cancer. 1975; 32: 502–508.
  • 26
    Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 1983; 221: 719–725.
  • 27
    Nagawa H, Paris P, Chauffert B, Martin F. Treatment of experimental liver metastases in the rat by continuous intraportal infusion of 5-fluorouracil and heparin: a pilot study. Anticancer Drugs. 1990; 1: 149–156.
  • 28
    Sylvester DM, Liu SY, Meadows GG. Augmentation of antimetastatic activity of interferon and tumor necrosis factor by heparin. Immunopharmacol Immunotoxicol. 1990; 12: 161–180.
  • 29
    Owen CAJr. Anticoagulant treatment of rats with Walker 256 carcinosarcoma. J Cancer Res Clin Oncol. 1982; 104(1–2): 191–193.
  • 30
    Drago JR, Weed P, Fralisch A. The evaluation of heparin in control of metastasis of Nb rat androgen-insensitive prostate carcinoma. Anticancer Res. 1984; 4: 171–172.
  • 31
    Pross M, Lippert H, Nestler G, et al. Effect of low molecular weight heparin on intra-abdominal metastasis in a laparoscopic experimental study. Int J Colorectal Dis. 2004; 19: 143–146.
  • 32
    Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost. 1998; 80: 10–23.
  • 33
    Thornes RD. Anticoagulant therapy in patients with cancer. J Ir Med Assoc. 1969; 62: 426–429.
  • 34
    Elias EG, Brugarolas A. The role of heparin in the chemotherapy of solid tumors: preliminary clinical trial in carcinoma of the lung. Cancer Chemother Rep. 1972; 56: 783–785.
  • 35
    Elias EG, Sepulveda F, Mink IB. Increasing the efficiency of cancer chemotherapy with heparin: “clinical study.” J Surg Oncol. 1973; 5: 189–193.
    Direct Link:
  • 36
    Elias EG, Shukla SK, Mink IB. Heparin and chemotherapy in the management of inoperable lung carcinoma. Cancer. 1975; 36: 129–136.
    Direct Link:
  • 37
    Stanford CF. Anticoagulants in the treatment of small cell carcinoma of the bronchus. Thorax. 1979; 34: 113–116.
  • 38
    Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA. 1981; 245: 831–835.
  • 39
    Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study No. 75. Cancer. 1984; 53: 2046–2052.
    Direct Link:
  • 40
    Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol. 1989; 7: 993–1002.
  • 41
    Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet. 1994; 343: 886–889.
  • 42
    Maurer LH, Herndon JE2nd, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol. 1997; 15: 3378–3387.
  • 43
    Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer. 1994; 74: 38–45.
    Direct Link:
  • 44
    Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004; 2: 1266–1271.
    Direct Link:
  • 45
    Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000; 83: 14–19.
  • 46
    Smorenburg SM, Hettiarachchi RJ, Vink R, Buller HR. The effects of unfractionated heparin on survival in patients with malignancy—a systematic review. Thromb Haemost. 1999; 82: 1600–1604.
  • 47
    Smorenburg SM, Vink R, Otten HM, Swaneveld F, Buller HR. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost. 2001; 86: 1586–1587.
  • 48
    Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol. 2004; 22: 1944–1948.
  • 49
    Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 23: 2130–2135.
  • 50
    Haas SK, Kakkar AK, Kemkes-Matthes B, et al. Topic 1—Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer—Results of the TOPIC studies. Presented at the XXth ISTH Congress, August 6–12, 2005. Abstract OR059.
  • 51
    Haas SK, Kakkar AK, Kemkes-Matthes B, et al. Topic 2—Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer—Results of the TOPIC studies. Presented at the XXth ISTH Congress, August 6–12, 2005 Abstract OR059.
  • 52
    Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006; 81: 758–767.
  • 53
    Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994; 309: 1286–1291.
  • 54
    HigginsJPT, GreenS, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Available at URL: http://www.cochrane.org/resources/handbook/hbook.htm Accessed July 1, 2005 Abstract OR059.
  • 55
    Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet. 1997; 350: 326–329.
  • 56
    Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials. 1995; 16: 62–73.
  • 57
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1–12.
  • 58
    Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17: 2815–2834.
    Direct Link:
  • 59
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22: 719–748.
  • 60
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177–188.
  • 61
    Cochran WG. The combination of estimates from different experiments. Biometrics. 1954; 10: 101–129.
  • 62
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539–1558.
    Direct Link:
  • 63
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557–560.
  • 64
    Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993; 2: 121–145.
  • 65
    Altman DG, Bland JM. Interaction revisited: the difference between two estimates [letter]. BMJ. Jan 25 2003; 326: 219.
  • 66
    Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991; 266: 93–98.
  • 67
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088–1101.
  • 68
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629–634.
  • 69
    Zacharski LR, Henderson WG, Forman WB, et al. Bleeding complications from warfarin anticoagulation in patients with malignancy. J Med. 1985; 16(5–6): 535–561.
  • 70
    Conti S, Guercini F, Iorio A. Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months. Pathophysiol Haemost Thromb. 2003; 33: 197–201.
  • 71
    Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet. 1992; 339: 1476.
  • 72
    Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1992; 326: 975–982.
  • 73
    Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992; 339: 441–445.
  • 74
    Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med. 1996; 100: 269–277.
  • 75
    Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost. 1999; 82: 947–952.
  • 76
    Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005; 23: 2123–2129.
  • 77
    Thodiyil P, Kakkar AK. Can low-molecular-weight heparins improve outcome in patients with cancer? Cancer Treat Rev. 2002; 28: 151–155.
  • 78
    Goerner A. The influence of anti-clotting agents on transplantation and growth of tumor tissue. J Lab Clin Med. 1930; 16: 369–372.
  • 79
    Terranova T, Chiossone F. Coagulation factors in the attachment of neoplastic cells released into the circulation [in Italian]. Boll Soc Ital Biol Sper. 1952; 28: 1224–1225.
  • 80
    Csaba G, Koroesi J, Horvath C, Mold K, Acs T. Effect of heparin-bound alkylating agents and enzyme inhibitors on neoplastic growth. Neoplasma. 1964; 11: 137–144.
  • 81
    Kudrijashov BA, Kalishevskaya TM, Kolomina SM. Blood anticoagulating system and malignant tumours. Nature. 1969; 222: 548–550.
  • 82
    Pross M, Lippert H, Misselwitz F, et al. Low-molecular-weight heparin (reviparin) diminishes tumor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadeno-carcinoma cells in rats after laparoscopy. Thromb Res. 2003; 110: 215–220.
  • 83
    Papaioannou AN, Polychronis AP, Kozonis JA, et al. Chemotherapy with or without anticoagulation as initial management of patients with operable colorectal cancer: a prospective study with at least 5 years follow-up. Recent Results Cancer Res. 1986; 103: 135–141.
  • 84
    Wereldsma JC, Bruggink ED, Meijer WS, Roukema JA, van Putten WL. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (Colorectal Adenocarcinoma Trial I). Cancer. 1990; 65: 425–432.
    Direct Link:
  • 85
    Fielding LP, Hittinger R, Grace RH, Fry JS. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet. 1992; 340: 502–506.
  • 86
    Lapierre F, Holme K, Lam L, et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology. 1996; 6: 355–366.
  • 87
    Nitti D, Wils J, Sahmoud T, et al. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983–1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer. 1997; 33: 1209–1215.
  • 88
    Torngren S, Rieger A. The influence of heparin and curable resection on the survival of colorectal cancer. Acta Chir Scand. 1983; 149: 427–429.
  • 89
    Kakkar AK, Hedges AR, Williamson R, Kakkar VV. Perioperative heparin therapy inhibits late death from metastatic cancer. Int J Oncol. 1995; 6: 885–888.
  • 90
    Kingston RD, Fielding JW, Palmer MK. Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer? Int J Colorectal Dis. 1993; 8: 111–115.
  • 91
    Kohanna FH, Sweeney J, Hussey S, Zacharski LR, Salzman EW. Effect of perioperative low-dose heparin administration on the course of colon cancer. Surgery. 1983; 93: 433–438.
  • 92
    Folkman J. Tumor angiogenesis and tissue factor. Nat Med. 1996; 2: 167–168.
  • 93
    Norrby K. Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis. 1993; 23( suppl 1): 141–149.
  • 94
    Norrby K, Ostergaard P. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp. 1996; 16: 8–15.
  • 95
    Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996; 2: 209–215.
  • 96
    Jones PH, Christodoulos K, Dobbs N, et al. Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. Br J Cancer. 2004; 91: 30–36.
  • 97
    Fisher B, Fisher ER. Anticoagulants and tumor cell lodgement. Cancer Res. 1967; 27: 421–425.
  • 98
    Grossi CE, Agostino D, Melamed M, Cliffton EE. The effect of human fibrinolysin on survival of carcinosarcoma 256 Walker cells in the blood. Cancer. 1961; 14: 957–962.
    Direct Link:
  • 99
    Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986; 315: 1650–1659.
  • 100
    Dvorak HF, Dvorak AM, Manseau EJ, Wiberg L, Churchill WH. Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst. 1979; 62: 1459–1472.
  • 101
    Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev. 1983; 2: 41–73.
  • 102
    Cliffton EE, Agostino D. Effect of inhibitors of fibrinolytic enzymes on development of pulmonary metastases. J Natl Cancer Inst. 1964; 33: 753–763.
  • 103
    Fisher B, Fisher ER. Experimental studies of factors which influence hepatic metastases. VII. Efect of anticoagulants. Surgery. 1961; 50: 240–247.
  • 104
    Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000; 96: 3302–3309.
  • 105
    Clarke N. Intracellular location of tissue thromboplastin and possible relation to fibrin deposits in human neoplasms. Nature. 1965; 205: 608–610.
  • 106
    Palumbo JS, Talmage KE, Liu H, La Jeunesse CM, Witte DP, Degen JL. Plasminogen supports tumor growth through a fibrinogen-dependent mechanism linked to vascular patency. Blood. 2003; 102: 2819–2827.
  • 107
    Thornes RD, Edlow DW, Wood SJr. Inhibition of locomotion of cancer cells in vivo by anticoagulant therapy. I. Effects of sodium warfarin on V2 cancer cells, granulocytes, lymphocytes and macrophages in rabbits. Johns Hopkins Med J. 1968; 123: 305–316.
  • 108
    Olander JV, Bremer ME, Marasa JC, Feder J. Fibrin-enhanced endothelial cell organization. J Cell Physiol. 1985; 125: 1–9.
    Direct Link:
  • 109
    Carney DH, Stiernberg J, Fenton JW2nd. Initiation of proliferative events by human alpha-thrombin requires both receptor binding and enzymic activity. J Cell Biochem. 1984; 26: 181–195.
    Direct Link:
  • 110
    Paris S, Pouyssegur J. Growth factors activate the Na+/H+ antiporter in quiescent fibroblasts by increasing its affinity for intracellular H+. J Biol Chem. 1984; 259: 10989–10994.
  • 111
    Galdal KS, Lyberg T, Evensen SA, Nilsen E, Prydz H. Thrombin induces thromboplastin synthesis in cultured vascular endothelial cells. Thromb Haemost. 1985; 54: 373–376.
  • 112
    Raben DM, Cunningham DD. Effects of EGF and thrombin on inositol-containing phospholipids of cultured fibroblasts: stimulation of phosphatidylinositol synthesis by thrombin but not EGF. J Cell Physiol. 1985; 125: 582–590.
    Direct Link:
  • 113
    Van Obberghen-Schilling E, Chambard JC, Paris S, L'Allemain G, Pouyssegur J. alpha-Thrombin-induced early mitogenic signalling events and G0 to S-phase transition of fibroblasts require continual external stimulation. EMBO J. 1985; 4: 2927–2932.
  • 114
    Levine MN. Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat Rev. 2002; 28: 145–149.
  • 115
    Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002; 162: 1729–1735.
  • 116
    Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349: 146–153.
  • 117
    Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost. 2003; 1: 1906–1913.
    Direct Link:
  • 118
    Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006; 12: 389–396.
  • 119
    Harenberg J, Kallenbach B, Martin U, et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res. 1990; 59: 639–650.
  • 120
    Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341: 793–800.
  • 121
    Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist. 2005; 10: 72–79.
  • 122
    Lyman GH, Kuderer NM. The strengths and limitations of meta-analyses based on aggregate data. BMC Med Res Methodol. 2005; 5: 14.
  • 123
    Mathew T, Nordstrom K. On the equivalence of meta-analysis using literature and using individual patient data. Biometrics. 1999; 55: 1221–1223.
    Direct Link:
  • 124
    Olkin I, Sampson A. Comparison of meta-analysis versus analysis of variance of individual patient data. Biometrics. 1998; 54: 317–322.
View Full Article (HTML) Get PDF (329K)